Big pharma just won't give up on amyloid theory. U
Post# of 1460
Quote:
Both Rippon and Matthews argue that there’s still more to interrogate on the amyloid theory, despite the recent clinical failure and the many that came before it.
“The course is not altogether too different from the one we have been charting,” Rippon said, noting the pharmaceutical industry’s combined efforts, different modalities and targets under investigation. “It takes time in this space, as we all know, to get there.”
https://www.fiercebiotech.com/biotech/fierce-...ind-reason